ZyVet® Animal Health, the animal health division of Zydus Lifesciences, has launched its first FDA-approved generic version of phenylpropanolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs. This move reflects ZyVet’s commitment to providing high-quality, affordable therapies for pets across the United States.
Urinary incontinence, often caused by a condition called urethral sphincter hypotonus, is most commonly seen in spayed female dogs and aging pets. It can lead to embarrassing accidents, affecting both dogs and their owners. ZyVet’s new generic medication offers reliable symptom relief and supports better long-term treatment compliance. Available in multiple strengths, it allows veterinarians to tailor dosing precisely for each pet, making it convenient for both veterinary teams and pet owners.
ZyVet’s expanding portfolio is helping to transform the veterinary industry, showing that generic products can be just as effective as their brand-name counterparts. Backed by Zydus Lifesciences’ 70 years of pharmaceutical expertise, ZyVet is at the forefront of bringing affordable innovation to animal healthcare.
Currently, less than 20% of FDA-approved animal drugs have a generic option, highlighting the ongoing need for cost-effective veterinary treatments. By introducing this generic phenylpropanolamine hydrochloride, ZyVet is making essential therapies more accessible to everyday pet owners and veterinarians.
